Trade First Wave BioPharma, Inc. - FWBI CFD

Trading Conditions

• Spread: 0.0820
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.001
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 2.729
• Open: 2.559
• 1-Year Change: -5.65%
• Day's Range: 2.559 - 2.759

First Wave BioPharma, Inc. Company profile

About First Wave BioPharma Inc

First Wave BioPharma, Inc., formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company's niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 immune checkpoint inhibitor-associated colitis and diarrhea in advanced oncology patients. It is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

Financial summary

BRIEF: For the nine months ended 30 September 2021, First Wave BioPharma Inc revenues was not reported. Net loss applicable to common stockholders increased from $23.4M to $73.2M. Higher net loss reflects Research and development expenses - Bala increase of 85% to $8.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$8.35 to -$10.31.